Paraneoplastic Neurologic Disorders, Volume 200 - Handbook of Clinical Neurology (May 8, 2024)_(0128239123)_(Elsevier)

Paraneoplastic Neurological Disorders extensively reviews Paraneoplastic Neurological Disorders in light of the most recent descriptions of autoantibodies against neuronal cell surface antigens (only partly associated with paraneoplastic disorders) and the introduction of new immuno-oncological drugs that can contribute to causing diseases that are pathogenetically indistinguishable from paraneoplastic syndromes. These two new developments have not been addressed in other volumes available on the market. Section 1 focuses on immunological defense mechanisms against tumors. Besides investigating the pathogenetic mechanisms of these disorders, this section will also explore what the introduction of new drugs used in immune checkpoint inhibitor cancer therapy is teaching us in terms of immunopathogenesis. The second section will present individual syndromes (phenotypical clinical manifestations) of the CNS, PNS, NMJ and muscle. These chapters will, however, be preceded by an epidemiological analysis and a chapter describing the clinical approach to patients with these disorders. Consideration will also be given in specific chapters to general therapeutic strategies and the techniques used to search for diagnostically relevant autoantibodies. Presentation of the individual diseases will be followed by a third section investigating the role of antibody markers, presented in three chapters differentiating cytoplasmic, nuclear and neuronal cell surface reactivities. The innovative component of the final two sections compared to previously published volumes lies in their presentation of the profile of paraneoplastic diseases by tumor type. Special attention will be given to thymoma (involved particularly with novel antibodies against surface antigens), and neuroendocrine tumours, which are as yet comparatively unexplored in the literature. Lastly, a clinical update will be provided on gynecological, hematological and testicular malignancies. The last section will address si Cover Series Page Series page Copyright Copyright Handbook of Clinical Neurology 3rd Series Available titles Foreword Foreword Preface Preface Contributors Contributors 1 Introduction and overview Introduction and overview of immunopathological mechanisms and future directions Immunopathogenic Mechanism of Paraneoplastic Neurologic Disorders11Abbreviations used in the chapter are listed Cytotoxic T Cell-Mediated PND-Associated with Antibodies Targeting Nuclear or Cytoplasmic Antig Antibody-Mediated Paraneoplastic Neurologic Disorders The Growing Number and Complexity of Neural Antibodies with Cancer Associations Greatest Unmet Need in Paraneoplastic Neurologic Disorders The Next Decade: Novel Biologics, Tolerization, and CAR-T Therapies A Brief Synopsis of Chapters References 2 Changing landscape in the field of paraneoplastic neurology: Personal perspectives over a 35-year career Introduction From Anecdotal Observations to Clinical-Pathologic Characterization of the Remote Effect Paraneoplastic Neurological Disorders, Volume 200 covers new, recent descriptions of autoantibodies against neuronal cell surface antigens (only partly associated with paraneoplastic disorders) and the introduction of new immuno-oncological drugs that can contribute to diseases that are pathogenetically indistinguishable from paraneoplastic syndromes. Besides investigating the pathogenetic mechanisms of these disorders, this book also explores what the introduction of new drugs used in immune checkpoint inhibitor cancer therapy are teaching us in terms of immunopathogenesis. Following sections present individual syndromes (phenotypical clinical manifestations) of the CNS, PNS, NMJ, and muscle. Finally, the book investigates the role of antibody markers that differentiate by cytoplasmic, nuclear, and neuronal cell surface reactivities. Side effects of the new immuno-oncological drugs increasingly used in cancer therapy are also covered.